Testosterone for Low Libido in Women

Testosterone is an androgen hormone naturally produced in women as well as men. Testosterone therapy has been studied in postmenopausal women with hypoactive sexual desire disorder (HSDD), a condition involving persistently low sexual desire that causes personal distress and is not better explained by another factor. Testosterone therapy for women should not be confused with testosterone treatment intended to produce male hormone levels.

Increase sexual desire, improve sexual satisfaction and arousal, increase energy and mood, build muscle, improve cognition, and provide general anti-aging or menopause benefits.

Randomized clinical trials show that testosterone therapy can produce a moderate improvement in sexual desire and related sexual function in appropriately selected postmenopausal women with hypoactive sexual desire disorder. On average, studies have found approximately one additional satisfying sexual event per month compared with placebo, along with improvements in sexual desire and reductions in sexual distress. Evidence does not establish testosterone as an effective treatment for general fatigue, depressed mood, cognitive decline, bone health, muscle strength, or broad anti-aging purposes in otherwise healthy postmenopausal women. Major professional guidance identifies HSDD as the evidence-supported indication for testosterone therapy in women after a thorough clinical assessment.

Testosterone may improve sexual desire, sexual satisfaction, and distress related to persistently low desire in some postmenopausal women who meet criteria for HSDD. The average benefit is meaningful for some women but should not be expected to produce a dramatic change in everyone.

Testosterone should not be expected to function as a general menopause cure, reliably increase energy, reverse aging, produce major muscle gains, improve memory, or treat every cause of low libido. Low sexual desire can have many contributors, and testosterone is not appropriate for every situation.

Clinical improvement in sexual desire may begin within several weeks. Studies suggest that benefit generally becomes apparent within the first few months. Lack of meaningful improvement after an adequate treatment trial should prompt reassessment rather than assuming more testosterone will produce a better result.

Testosterone can cause androgen-related effects such as acne and increased facial or body hair. Keeping testosterone exposure within the normal physiologic range for women is important. Supraphysiologic testosterone levels can increase the risk of additional androgenic effects. Long-term safety data in women remain limited, particularly beyond approximately two years of treatment. Compounded testosterone products and preparations designed for men can create dosing and quality concerns when used in women. Evaluation and monitoring by a qualified healthcare professional are important.

Highly variable. Because treatment for women may involve off-label or compounded formulations in the U.S., medication costs can range roughly from $30–$100+ per month, with consultation and laboratory costs potentially additional.